CPhI & P-MEC China Indicate Expansion of the Chinese Domestic Market

August 10, 2015
Pharmaceutical Technology Editors

Unlike pharmaceutical manufacturing in the West, China’s growth is not merely a result of the increasing sales of finished formulations in highly regulated markets.

This year marked the 15th anniversary of CPhI China, and 10 years of partnership with P-MEC. CPhI & P-MEC China, hosted by UBM EMEA and CCCMHPIE, and co-organized by UBM Sinoexpo, had a successful show at the Shanghai New International Expo Centre (SNIEC), June 24–26, 2015. The networking and knowledge-sharing event has grown in lieu with the rapidly expanding Chinese market.

According to the CPhI Insights Report, unlike pharmaceutical manufacturing in the West, China’s growth is not merely a result of the increasing sales of finished formulations in highly regulated markets. The economic and cost advantages from large-scale API batches are among the key drivers attracting other pharma players to the region.

The strong interest in the Chinese market was reflected at CPhI & P-MEC China, which saw more than 2600 global companies exhibiting across the 150,000 square meter floor space with approximately 64,000 visitors in attendance. The portfolio of content included more than 70 onsite conferences and activities covering a range of key topics such as contract services, environmental protection, and clean technology. The 2nd P-MEC Summit and International Summit for Pharmaceutical Packaging & Drug Delivery System highlighted the important role that P-MEC and Innopack China play in the industry.

Jie Wang, vice-president at Zhejiang Huahai Pharmaceutical Co., Ltd, commented in a press statement that CPhI offers a one-stop place to meet with clients and suppliers at the same time. 

Source: CPhI China

Related Content:

Industry News | PharmTech News